REMIT-DAPA study at PHRI
completed

The objective of the REMIT-DAPA study was to determine if in patients with recently-diagnosed type 2 diabetes (T2DM), a 12-week course of forxiga, metformin, basal insulin glargine and lifestyle approaches will achieve drug-free diabetes remission in a higher proportion of patients than standard diabetes therapy at 24 weeks (three months after the drugs are stopped).

Participants will be randomized to two  treatment groups:

a) a 12-week course of treatment with forxiga, metformin, insulin glargine and lifestyle therapy, and

(b) standard diabetes therapy, and followed for a total of 64 weeks.

Primary endpoint:

Diabetes remission evaluated at 24 weeks after randomization.

Study Type

Interventional - Drug

Study Design

Multicenter,open label RCT

NO. of Countries

1

NO. of Sites

6

NO. of Participants

154

Study Period

2015 - 2018

Sponsor

PHRI

AstraZeneca

Back To Top